Table 3 Lipid and BP treatment and control rates by CKD stage in US adults ≥20 years of age with CKD Stage 1–4* based on 2001–2010 NHANES participants
Variable | No CKD | All CKD | CKD Stage: | P † | ||||
|---|---|---|---|---|---|---|---|---|
(n=8,487) | (n=1,428) | 1 | 2 | 3a | 3b | 4 | ||
(n=285) | (n=337) | (n=545) | (n=201) | (n=60) | ||||
Lipid treatment and control (%)‡ | ||||||||
Antihyperlipidemics§ | 11.8 (0.5) | 30.4 (1.5) | 18.1 (2.9) | 31.4 (2.4) | 33.0 (2.5) | 40.4 (4.2) | 44.8 (7.1) | <0.001 |
LDL-C <100 mg/dL | ND | 40.0 (1.7) | 35.8 (3.6) | 38.2 (3.6) | 38.4 (2.4) | 52.8 (3.9) | 50.7 (8.5) | 0.135 |
BP treatment and control (%)‡ | ||||||||
Antihypertensives║ | 17.4 (0.6) | 54.4 (1.6) | 30.2 (3.2) | 54.8 (3.7) | 62.0 (2.5) | 71.3 (3.4) | 78.9 (5.8) | <0.001 |
BP ≤130/80 mmHg | ND | 44.6 (1.8) | 49.5 (4.0) | 42.4 (3.7) | 41.6 (2.9) | 52.3 (4.3) | 30.2 (6.2) | 0.019 |